Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • IRAK1/4
      • RIPK1
      • COVID-19
    • Partnered Programs
      • BerGenBio
      • Daiichi-Sankyo
      • Forma
      • Grifols
      • Kissei
      • Lilly
      • Medison
      • Knight
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Sep 27, 2018 7:30am EDT

Rigel to Host Investor & Analyst Day in New York City on October 4, 2018

Sep 24, 2018 7:30am EDT

Rigel to Present at the Cantor Global Healthcare Conference

Aug 29, 2018 7:30am EDT

Rigel to Present at the 20th Annual Global Investment Conference in New York City

Aug 08, 2018 4:07pm EDT

Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update

Aug 01, 2018 7:30am EDT

Rigel Announces Conference Call and Webcast to Report Second Quarter 2018 Financial Results

Jun 26, 2018 7:30am EDT

Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases

Jun 20, 2018 4:01pm EDT

Rigel Announces Poster Presentations at FOCIS Annual Meeting

Jun 12, 2018 7:30am EDT

Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA

May 31, 2018 7:30am EDT

Rigel to Present at Jefferies 2018 Global Healthcare Conference

May 30, 2018 7:30am EDT

Rigel Appoints Dean Schorno as Chief Financial Officer

  • Previous
  • 1…
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • …36
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2023 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

REZLIDHIA is a trademark of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin